On January 2, Glonghui reported that Baixinan-B (02185.HK) announced that on December 31, 2024, the company and Zhejiang Baixinan signed an investment agreement and shareholder agreement with investors (namely, Jiaxing Guojian Baixin Private Equity Partnership (Limited Partnership)). According to this agreement, the investors conditionally agreed to inject approximately 0.1556 billion yuan into Zhejiang Baixinan, of which about 37.88 million yuan will be recorded as the paid-in registered capital of Zhejiang Baixinan, while the remaining approximately 0.11772 billion yuan will be recorded as its capital reserve.

Upon completion, Zhejiang Baixinan will be owned 54.6792% by the company and 45.3208% by the investors. As a result, the company's equity in Zhejiang Baixinan will be diluted from 100% to approximately 54.6792%. Zhejiang Baixinan will still be a subsidiary of the company, and its accounts will continue to be consolidated into the company's accounts.

Zhejiang Baixinan (i.e., Zhejiang Baixinan Medical Instruments Co., Ltd.) is a limited liability company established in China on October 15, 2024. As of the date of this announcement, it is a wholly-owned subsidiary of the company, primarily engaged in the production and commercialization of Innovative Medical Management medical instruments. The funds raised from the investment will be used as working capital for Zhejiang Baixinan to develop its main Business.